Services

  • Health Economics
  • Systematic Literature Review
  • Meta-analysis
  • Medical Writing

Heath Economic Modeling and Analysis

DEVOTE Model of Type 2 Diabetes
Type 2 diabetes cost-utility model schematic (Pollock et al. 2019).

Covalence has a wealth of health economic modeling expertise, spanning numerous therapy areas, modeling objectives, model structures, and technology platforms.

Furthermore, in the reimbursement context, Covalence has consistently delivered models that have resulted in successful reimbursement of the health technology of interest, including models that have formed the basis of submissions to the National Institute for Health and Care Excellence (NICE) and the Canadian Agency for Drugs and Technologies in Health (CADTH).

Systematic Literature Review

Sourcerer
Sourcerer, Covalence's in-house, custom-built platform for literature screening.

The Covalence team has performed dozens of systematic literature reviews, including reviews that have formed the basis of widely-cited peer-reviewed manuscripts and reimbursement submissions.

Since systematic literature reviews often form the bedrock of evidence synthesis efforts such as network meta-analyses and evidence generation efforts such as cost-utility modeling, Covalence takes the process very seriously. So seriously, in fact, that we've developed our own in-house software for conducting systematic literature reviews: Sourcerer. Sourcerer allows Covalence to rapidly screen large volumes of literature and provide bibliographies and literature review outputs in a consistent format.

Meta-analysis

Pollock et al. network meta-analysis.
Pollock RF, et al. Expert Rev Anticancer Ther. 2021;21(3):341-349.

Covalence has extensive experience running meta-analyses, including everything from pooling of data from multiple trials of the same interventions, through indirect treatment comparisons, to complex network meta-analyses.

In the interests of ensuring that meta-analyses are conducted and reported in accordance with best practice guidelines from ISPOR and NICE, Covalence sponsors the BUGSnet project and works in close collaboration with the University of Waterloo to steward its ongoing development.

Medical Writing

J Cancer Res Clin Oncol. 2020;146(10):2575-2587.
Walter et al. J Cancer Res Clin Oncol. 2020;146(10):2575-2587.

Medical writing and value communications are among the core services offered by Covalence. This includes the preparation of systematic literature reviews, global value dossiers and value messages to support reimbursement as well as landscape reviews, manuscripts, posters, slide kits and medical education resources.

Attention to detail and a desire to produce the highest quality deliverables possible is at the cornerstone of everything we do. We work closely with clients to ensure that each project is tailored to meet the specific needs of the market and therapy area in question ensuring that all deliverables are customized and underline the nuances and value of each individual intervention.

The Covalence team have a wealth of experience in medical writing across a broad range of therapy areas with particular expertise in diabetes, oncology and virology. Examples of recent manuscripts published by the Covalence team can be found here.

Delphi Panels

About Us

Richard Pollock MA MSciSenior Health Economist, UK

Cartoon image of Richard Pollock

Richard is a Senior Health Economist and Director at Covalence.

Having graduated with a first-class MSci in Natural Sciences from the University of Cambridge in 2007, he has since worked as a health economist for over 14 years. He has developed models, formulated analysis plans, and managed health technology assessment submissions that have contributed to successful reimbursement decisions at the SMC, NICE, AMCP and CADTH, and has published over 60 peer-reviewed publications and dozens of congress and conference presentations.

Johannes Pöhlmann BA MSc MPHHealth Economist, Germany

Cartoon image of Johannes Pöhlmann

Johannes is a Health Economist at Covalence.

Johannes graduated with a BA in Political Science and Economics from the University of Munich in 2013. He went on to complete an MSc in Demography & Health at the London School of Hygiene and Tropical Medicine in 2015 and an MPH from the University of Munich in 2016. He has since worked on health economic evaluations of public health interventions and health technology assessments, including for biosimilar infliximab in Switzerland, at the Zurich University of Applied Sciences (Switzerland) and on autonomic dysfunction in heart failure at the University of Mainz (Germany).

Jayne Smith-Palmer DPhilSenior Consultant, Switzerland

Cartoon image of Jayne Smith-Palmer

Jayne is a Senior Consultant at Covalence, specialising in medical writing, evidence synthesis, and value communication.

Jayne graduated with a BSc in Biology from the University of St Andrews in 2002. She went on to complete a DPhil in biophysics at Oxford University in collaboration with the National Institute for Medical Research, London, UK and the National Heart Lung and Blood Institute, Bethesda, MD, USA. Since then, she has gained over 15 years of experience in medical writing and value communications, and has coauthored over 30 publications in the peer-reviewed literature.

Waqas Ahmed MSc MPharmHealth Economist, UK

Cartoon image of Waqas Ahmed

Waqas is a Health Economist at Covalence.

Waqas graduated with a first-class MPharm from University College London in 2017 and went on to obtain a distinction in his MSc in Health Economics at the University of York in 2020. He subsequently joined PHMR Ltd in London as a health economist where he worked on several patient-reported outcomes projects. Waqas joined Covalence as a Health Economist in March 2022 where he continues to work on a variety of health economic modeling and evidence synthesis projects across a wide range of therapy areas.

Neesha Nanu BSc MScSenior Evidence Synthesis Consultant, UK

Cartoon image of Neesha Nanu

Neesha is a Senior Evidence Synthesis Consultant at Covalence.

Neesha graduated with a BSc in Biomedical Science from the University of Kent in 2015 and went on to complete an MSc in epidemiology at Imperial College London. She subsequently worked as a Research Assistant at Imperial where she worked on a continuously-updated systematic literature review funded by the World Cancer Research Fund International on the role of diet, nutritional status, anthropometric characteristics and physical activity in cancer prevention and prognosis. Neesha joined Covalence in 2022 where she continues to work on epidemiological research and novel evidence synthesis projects.

Publications

2021–22

  • Rønborg S, Grand TS, Brandi H, Pollock RF. ITULAZAX® versus Alutard SQ® in the Treatment of Allergic Rhinitis Induced by Pollen from the Birch Homologous Group: A Cost-minimization Modeling Analysis from the Danish Societal Perspective. Clin Transl Allergy. 2022. In press.
  • Pollock RF, Kalra PA, Kalra PR, Ahmed FZ. A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose. Adv Ther. 2022. Online publication ahead of print.
  • Hu S, Liu L, Pollock RF, Pöhlmann J, Wu D, Zhang Y. Intravenous Iron for the Treatment of Iron Deficiency Anemia in China: A Patient-level Simulation Model and Cost-utility Analysis Comparing Ferric Derisomaltose with Iron Sucrose. J Med Econ. 2022;25(1):561-570.
  • Pöhlmann J, Bergenheim K, Sanchez J-JG, Rao N, Briggs A, Pollock RF. Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts. Diabetes Ther. 2022;13(4):651-677.
  • Pollock RF, Norrbacka K, Boye KS, Osumili B, Valentine WJ. The PRIME type 2 diabetes model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus. J Med Econ. 2022;25(1):393-402.
  • Felizzi F, Paracha N, Pöhlmann J, Ray J. Mixture Cure Models in Oncology: A Tutorial and Practical Guidance. Pharmacoecon Open. 2021;5(2):143–155.
  • Pollock RF, Colaone F, Shergill S, Brennan VK, Agirrezabal I. Effects of Trial Population Selection on Quality of Life and Healthcare Decision-Making: A Systematic Review and Example in the Treatment of Hepatocellular Carcinoma with Radioembolization. Clinicoecon Outcomes Res. 2021;13:835–841.
  • Pollock RF, Muduma G. An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland. Clinicoecon Outcomes Res. 2021;13:9–18.
  • Pollock RF, Brennan VK, Shergill S, Colaone F. A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials. Expert Rev Anticancer Ther. 2021;21(3):341–349.

2020

  • Brennan VK, Colaone F, Shergill S, Pollock RF. A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK. J Med Econ. 2020;23(12):1588-1597.
  • Pollock RF, Brennan VK, Peters R, Paprottka PM. Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. Expert Rev Anticancer Ther. 2020;20(11):997-1009.
  • Igarashi A, Hunt B, Wilkinson L, Langer J, Pollock RF. Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis. Adv Ther. 2020;37(10):4446-4457.
  • Walter T, Hawkins NS, Pollock RF, Colaone F, Shergill S, Ross PJ. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. J Cancer Res Clin Oncol. 2020;146(10):2575-2587.
  • Smith-Palmer J, Cerri K, Sbarigia U, Chan EKH, Pollock RF, Valentine WJ, Bonroy K. Impact of Stigma on People Living with Chronic Hepatitis B. Patient Relat Outcome Meas. 2020;11:95-107.
  • Pollock RF, Muduma G. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. J Med Econ. 2020;23(7):751-759.
  • Pollock RF, Colaone F, Guardiola L, Shergill S, Brennan VK. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. J Med Econ. 2020;23(6):593-602.
  • Loughnane F, Muduma G, Pollock RF. Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland. Adv Ther. 2020;37(3):1218-1232.
  • Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol. 2020 Feb;13(2):187-195.

Contact

Email

Project-related or other enquiries can be sent to info@covalence-research.com.

Phone

UK
+44 20 8638 6525

USA
+1 (202) 697-9435

Switzerland
+41 44 585 19 85‬

Address

Covalence is headquartered at Rivers Lodge, West Common, Harpenden, AL5 2JD.